[Translation] A single-arm, open-label, single-center clinical trial evaluating the safety and pharmacokinetic characteristics of human coagulation factor VIII after a single dose in patients with severe hemophilia A (factor VIII deficiency).
1.主要目的
评价人凝血因子Ⅷ在重型血友病A(FⅧ活性<1%)患者中单次给药后的药代动力学特征,为本品的再注册提供依据。
2.次要目的
1)评价人凝血因子Ⅷ在重型血友病A(FⅧ活性<1%)患者中单次给药后的药效动力学特征;
2)评价人凝血因子Ⅷ在重型血友病A(FⅧ活性<1%)患者中单次给药后以及出血事件按需治疗后的安全性。
[Translation] 1. Primary Objective: To evaluate the pharmacokinetic characteristics of human coagulation factor VIII in patients with severe hemophilia A (FVIII activity <1%) after a single dose, providing a basis for the re-registration of this product.
2. Secondary Objectives:
1) To evaluate the pharmacodynamic characteristics of human coagulation factor VIII in patients with severe hemophilia A (FVIII activity <1%) after a single dose;
2) To evaluate the safety of human coagulation factor VIII in patients with severe hemophilia A (FVIII activity <1%) after a single dose and after on-demand treatment of bleeding events.